Shikonin protects mitochondria through the NFAT5/AMPK pathway for the treatment of diabetic wounds

Figure 1 Effects of shikonin on cell viability and COX-2 expression in hypertonic cell models. A: Cell viability of hypertonic cell model and COX-2 expression; B: Cell viability of shikonin treated cell; C: COX-2 expression of shikonin treated cell; D: Cell viability of shikonin treated hypertonic cell models and COX-2 expression. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001.